20 December 2024 - Approximately 300 more people with cystic fibrosis in the US are now eligible for a medicine that treats the underlying cause of their disease for the first time.

Vertex Pharmaceuticals today announced the US FDA has approved the expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene or a mutation that is responsive to Trikafta based on clinical and/or in vitro data.

Read Vertex Pharmaceuticals press release